A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (INI1-negative tumors cohort) (NCT02601950)

S. Stacchiotti, J. Y. Blay, R. L. Jones, G. D.D. Demetri, O. Mir, A. Italiano, D. Thomas, T. W.W. Chen, P. Schöffski, T. Gil, T. Jahan, G. Cote, R. Ratan, S. Attia, M. Roche, S. Daigle, I. Sapir, A. Clawson, M. Gounder

Research output: Contribution to journalArticle

Original languageEnglish (US)
Pages (from-to)viii580
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume29
DOIs
StatePublished - Oct 1 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Stacchiotti, S., Blay, J. Y., Jones, R. L., Demetri, G. D. D., Mir, O., Italiano, A., Thomas, D., Chen, T. W. W., Schöffski, P., Gil, T., Jahan, T., Cote, G., Ratan, R., Attia, S., Roche, M., Daigle, S., Sapir, I., Clawson, A., & Gounder, M. (2018). A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (INI1-negative tumors cohort) (NCT02601950). Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii580. https://doi.org/10.1093/annonc/mdy299.010